All In Biotech

Drug Trial Radar · NCT05974345

In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease

In Silico Non Interventional Secondary Use of Data Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease

Last checked: Nov 19, 2026Latest source record: May 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

204,691

Actual

Start

Nov 3, 2023

Primary completion

Dec 15, 2023

Study completion Dec 15, 2023

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Aug 3, 2023

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study CKJX839B1FR01 in an In silico trial to predict the efficacy of Inclisiran therapy on major adverse cardiovascular events (MACE) and cardiovascular (CV) death in virtual patients with atherosclerotic cardiovascular disease (ASCVD) and elevated LDL-C.

Conditions

  • Atherosclerotic Cardiovascular Disease

Interventions

  • Inclisiran sodiumDrug

    Drug: Inclisiran sodium 300 mg virtually subcutaneously administered on Day 1, Month 3 (Day 90) and every 6 months thereafter until end of simulation.

  • PlaceboDrug

    Drug: Placebo virtually subcutaneously administered on Day 1, Month 3 (Day 90) and every 6 months thereafter until end of simulation.

  • EzetimibeDrug

    Drug: Ezetimibe 10 mg virtually orally once a day until end of simulation.

  • EvolocumabDrug

    Drug: Evolocumab 140 mg virtually subcutaneously administered every two weeks until end of simulation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to the first occurrence between trial start and end of follow-up of any component of 3P-MACE (composite of CV death, non-fatal MI or non-fatal ischemic stroke)Time frame: 5 years of follow-up
  2. Time to the first occurrence between trial start and end of follow-up of CV deathTime frame: 5 years of follow-up

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Rueil-Malmaison, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.